By Karen Freifeld
(Reuters) – A new version of a bill that would restrict U.S. business with China’s WuXi AppTec, BGI and other biotechnology companies of concern would allow companies until 2032 to end work with the Chinese firms, extending the amount of time to find new partners.
The latest Biosecure Act also adds WuXi Biologics to a list of biotech companies of concern. The other companies on the list are BGI, MGI, Complete Genomics and WuXi AppTec.
The bill will be introduced on Friday and a U.S. House of Representatives committee is expected to decide next week whether to move the bill forward, according to a House Committee on Oversight and Accountability spokesperson. The markup, expected Wednesday, is a procedural step in the process to the bill’s possibly becoming law. A similar Senate bill was approved by a committee there in March
(Reporting by Karen Freifeld; Editing by Chizu Nomiyama)
Disclaimer: This report is auto generated from the Reuters news service. ThePrint holds no responsibilty for its content.